

Dr. Milton H. Grannatt Joins SymBio as Outside Director

TOKYO, Japan, March 28, 2013 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida, "SymBio") today announced the appointment of Dr. Milton H. Grannatt, retired Vice President of Global Business Development, Novartis Pharmaceuticals Corporation, to its Board of Directors. Dr. Grannatt has spent 24 years working for global healthcare companies in the U.S., Japan and Switzerland. With the appointment of Dr. Grannatt as outside director at the 8th General Shareholders Meeting, the Board is comprised of six directors, four of whom are Outside Directors.

"We are very pleased to welcome Milton to SymBio's Board. He brings to SymBio a wealth of experience and superb track record of success leading business development, mergers and acquisitions, and finance at global healthcare companies. His contributions to the Board will guide us as we continue to build SymBio into a global specialty pharmaceutical company and create value for our shareholders" said Fuminori Yoshida, President and Chief Executive Officer at SymBio.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida, who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs in the areas of oncology, hematology and autoimmune disease.

[Contact]

SymBio Pharmaceuticals Limited.

Shoichi Den

Director, Human Resources Department

Tel: +081(0)3 5472 1125

URL: <http://www.symbiopharma.com>